Palbociclib shows promise in patients with hormone-resistant breast cancer
Friday, February 20, 2015 - 14:30
in Health & Medicine
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.